[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.189.139. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Download PDF
Figure 1.
Design of the study. Patients were scheduled for direct laryngoscopy/bronchoscopy (DL) at 3-month intervals and were randomized to receive a single treatment with photodynamic therapy (PDT) either 6 or 18 months after enrollment. Asterisk indicates randomization to either the early or late treatment group.

Design of the study. Patients were scheduled for direct laryngoscopy/bronchoscopy (DL) at 3-month intervals and were randomized to receive a single treatment with photodynamic therapy (PDT) either 6 or 18 months after enrollment. Asterisk indicates randomization to either the early or late treatment group.

Figure 2.
Figure 2. Response to photodynamic therapy (PDT). Median severity scores at each 3-month interval relative to scores at initial direct endoscopy are shown for the early group, which received PDT 6 months after enrollment (A), and the control group (ie, the late group), which received PDT 18 months after enrollment (B). Error bars represent range; diagonal hash marks, a break in the linear scale of the y-axis.

Figure 2. Response to photodynamic therapy (PDT). Median severity scores at each 3-month interval relative to scores at initial direct endoscopy are shown for the early group, which received PDT 6 months after enrollment (A), and the control group (ie, the late group), which received PDT 18 months after enrollment (B). Error bars represent range; diagonal hash marks, a break in the linear scale of the y-axis.

Figure 3.
Relationship between immune response and disease severity after photodynamic therapy (PDT). Results of multiple assays across time for the threshold of human papillomavirus E6 protein required for the induction of 2 cytokines that regulate immune response are shown for 3 patients (A, B, and C). Interferon γ (IFN-γ) is a positive regulator, and interleukin 10 (IL-10) is immunosuppressive. Bars indicate the disease severity score at each assay time; transposition marks, a break in the linear scale of the x-axis.

Relationship between immune response and disease severity after photodynamic therapy (PDT). Results of multiple assays across time for the threshold of human papillomavirus E6 protein required for the induction of 2 cytokines that regulate immune response are shown for 3 patients (A, B, and C). Interferon γ (IFN-γ) is a positive regulator, and interleukin 10 (IL-10) is immunosuppressive. Bars indicate the disease severity score at each assay time; transposition marks, a break in the linear scale of the x-axis.

Table 1.  
Baseline Characteristics of the Patient Groups
Baseline Characteristics of the Patient Groups
Table 2.  
Treatment Variables for the Patient Groups
Treatment Variables for the Patient Groups
Table 3.  
Statistical Analyses of Response to Photodynamic Therapy
Statistical Analyses of Response to Photodynamic Therapy
Table 4.  
Relationship Between Demographic and Treatment Variables and Response to Photodynamic Therapy
Relationship Between Demographic and Treatment Variables and Response to Photodynamic Therapy
1.
Steinberg  BMTopp  WSchneider  PSAbramson  AL Laryngeal papillomavirus infection during clinical remission. N Engl J Med 1983;3081261- 1264
PubMedArticle
2.
Abramson  ALNouri  MMullooly  VFisch  GSteinberg  BM Latent human papillomavirus infection is comparable in the larynx and trachea. J Med Virol 2004;72473- 477
PubMedArticle
3.
Broker  TRJin  GCroom-Rivers  A  et al.  Viral latency: the papillomavirus model. Dev Biol (Basel) 2001;106443- 451
PubMed
4.
Bonagura  VRHatam  LDeVoti  JZeng  FSteinberg  BM Recurrent respiratory papillomatosis: altered CD8(+) T-cell subsets and TH1/TH2 cytokine imbalance. Clin Immunol 1999;93302- 311
PubMedArticle
5.
DeVoti  JASteinberg  BMRosenthal  DW  et al.  Failure of gamma interferon but not interleukin-10 expression in response to human papillomavirus type 11 E6 protein in respiratory papillomatosis. Clin Diagn Lab Immunol 2004;11538- 547
PubMed
6.
Healy  GBGelber  RDTrowbridge  ALGrundfast  KMRuben  RJPrice  KN Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. N Engl J Med 1988;319401- 407
PubMedArticle
7.
Kashima  HLeventhal  BClark  K  et al.  Interferon α-Na in juvenile onset recurrent respiratory papillomatosis: results of a randomized study in twelve collaborative institutions. Laryngoscope 1988;98334- 340
PubMed
8.
Auborn  KJ Therapy for recurrent respiratory papillomatosis. Antivir Ther 2002;71- 9
PubMed
9.
Rosen  CABryson  PC Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results. J Voice 2004;18248- 253
PubMedArticle
10.
Pashley  NR Can mumps vaccine induce remission in recurrent respiratory papilloma? Arch Otolaryngol Head Neck Surg 2002;128783- 786
PubMedArticle
11.
Pransky  SMMagit  AEKearns  DBKang  DRDuncan  NO Intralesional cidofovir for recurrent respiratory papillomatosis in children. Arch Otolaryngol Head Neck Surg 1999;1251143- 1148
PubMedArticle
12.
Shikowitz  MJSteinberg  BMAbramson  AL Hematoporphyrin derivative therapy of papillomas: experimental study. Arch Otolaryngol Head Neck Surg 1986;11242- 46
PubMedArticle
13.
Abramson  ALShikowitz  MJMullooly  VMSteinberg  BMAmela  CARothstein  HR Clinical effects of photodynamic therapy on recurrent laryngeal papillomas. Arch Otolaryngol Head Neck Surg 1992;11825- 29
PubMedArticle
14.
Abramson  ALShikowitz  MJMullooly  VMSteinberg  BMHyman  RB Variable light dose effect on photodynamic therapy of laryngeal papillomas. Arch Otolaryngol Head Neck Surg 1994;120852- 855
PubMedArticle
15.
Shikowitz  MJAbramson  ALFreeman  K  et al.  Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results. Laryngoscope 1998;108962- 967
PubMedArticle
16.
Ronn  AMNouri  MLofgren  LA  et al.  Human tissue levels and plasma pharmacokinetics of temoporfin (Foscan, mTHPC). Lasers Med Sci 1996;11267- 272Article
17.
Ronn  AMBatti  JLee  CJ  et al.  Comparative biodistribution of meta-tetra(hydroxyphenyl) chlorin in multiple species: clinical implications for photodynamic therapy. Lasers Surg Med 1997;20437- 442
PubMedArticle
18.
Lofgren  LARonn  AMAbramson  AL  et al.  Photodynamic therapy using m-tetra (hydroxyphenyl) chlorin: an animal model. Arch Otolaryngol Head Neck Surg 1994;1201355- 1362
PubMedArticle
19.
Dedo  HHYu  KC CO2 laser treatment in 244 patients with respiratory papillomas. Laryngoscope 2001;1111639- 1644
PubMedArticle
20.
Dougherty  TJGomer  CJHenderson  BW  et al.  Photodynamic therapy. J Natl Cancer Inst 1998;90889- 905
PubMedArticle
21.
Korbelik  MDougherty  GJ Photodynamic therapy–mediated immune response against subcutaneous mouse tumors. Cancer Res 1999;591941- 1946
PubMed
22.
van Duijnhoven  FHAalbers  RIRovers  JPTerpstra  OTKuppen  PJ The immunological consequences of photodynamic treatment of cancer, a literature review. Immunobiology 2003;207105- 113
PubMedArticle
23.
Ohashi  PSDeFranco  AL Making and breaking tolerance. Curr Opin Immunol 2002;14744- 759
PubMedArticle
24.
Bonagura  VRVambutas  ADeVoti  JA  et al.  HLA alleles, IFN-γ responses to HPV-11 E6, and disease severity in patients with recurrent respiratory papillomatosis. Hum Immunol 2004;65773- 782
PubMedArticle
25.
Vambutas  ABonagura  VRReed  EF  et al.  Polymorphism of transporter associated with antigen presentation 1 as a potential determinant for severity of disease in recurrent respiratory papillomatosis caused by human papillomavirus types 6 and 11. J Infect Dis 2004;189871- 879
PubMedArticle
Original Article
February 2005

Clinical Trial of Photodynamic Therapy With Meso-Tetra (Hydroxyphenyl) Chlorin for Respiratory Papillomatosis

Arch Otolaryngol Head Neck Surg. 2005;131(2):99-105. doi:10.1001/archotol.131.2.99
Abstract

Objective  To determine the efficacy of photodynamic therapy (PDT) with meso-tetra (hydroxyphenyl) chlorin (m-THPC) photosensitizer for recurrent respiratory papillomatosis.

Design  Parallel-arm, randomized trial of patients requiring surgery at least 3 times yearly with single PDT 6 or 18 months after enrollment and 12-month follow-up. Disease extent was scored and papillomas were removed during direct endoscopy every 3 months after enrollment.

Setting  Tertiary medical centers.

Patients  Of 23 patients aged 4 to 60 years enrolled in the study, 15 patients, plus 2 in the late group without PDT owing to airway risk, completed the study. Six patients withdrew voluntarily after PDT.

Intervention  Intravenous administration of m-THPC 6 days before direct endoscopic PDT with 80 to 100 J of light for adults and 60 to 80 J for children.

Main Outcome Measures  Difference in severity scores between the early and late groups and between pre- and post-PDT scores for all patients. Secondary measures were the associations between baseline characteristics and response and changes in immune response and the prevalence of latent viral DNA.

Results  There were significant differences between groups, with marked improvement in laryngeal disease across time after PDT (P = .006). Five of 15 patients were in remission 12 to 15 months after treatment, but there was recurrence of disease after 3 to 5 years. Tracheal disease was not responsive to PDT. No change occurred in the prevalence of latent human papillomavirus DNA. The immune response to virus improved with clinical response.

Conclusions  Use of m-THPC PDT reduces the severity of laryngeal papillomas, possibly through an improved immune response. Failure to maintain remission with time suggests that this is not an optimal treatment.

Recurrent respiratory papillomatosis (RRP) is a potentially life-threatening disease with a clinical course marked by multiple recurrences. Human papillomavirus (HPV) types 6 and 11, which cause RRP, exist as latent infections in morphologically normal tissue of the airway and are believed to be the source of recurrent disease.1,2 To achieve cure, therapy must either eliminate latent infection or prevent its activation. The HPV is a commensal organism in humans, with widespread latent infection usually suppressed by the host immune system.3 Results of recent studies4,5 suggest that the immune response to HPV proteins is altered in patients with RRP.

Numerous treatment modalities have been tried for RRP, with limited success in preventing recurrent disease.68 Current experimental treatments include adjuvant indole-3-carbinol,9 intralesional mumps vaccine,10 and cidofovir injections.11 These therapies seem to be effective in a subset of patients, but not all patients respond, and the mechanisms for the intralesional therapies are not known. Direct laryngoscopy with mechanical or carbon dioxide (CO2) laser surgery is still the most common method of treatment today and the only approved treatment for RRP.

Photodynamic therapy (PDT) was originally developed for the diagnosis and treatment of cancer. Using a rabbit model, Shikowitz et al12 were the first to demonstrate the effect of PDT on papillomavirus-induced lesions. Previous clinical trials1315 evaluated the efficacy of PDT with the photosensitizer dihematoporphyrin-ether on RRP. Dihematoporphyrin-ether PDT induced a 50% decrease in the disease severity score13 but caused prolonged photosensitivity for 6 weeks to 3 months. Therefore, we searched for new photosensitizers with improved properties. Meso-tetra (hydroxyphenyl) chlorin (m-THPC) has better tissue selectivity and a shorter washout time16,17 and was effective in preclinical studies of papillomavirus-induced lesions.18

The primary objective of this trial is to test the hypothesis that a single adjunct treatment with m-THPC PDT reduces the frequency of recurrent disease compared with surgery alone. Secondary objectives are to determine whether m-THPC PDT reduced the prevalence of latent laryngeal HPV infection or altered the immune response to HPV protein.

METHODS
STUDY DESIGN

The design of this multicenter, parallel-arm, randomized, controlled study is shown in Figure 1. Disease extent was scored and papillomas were removed during direct endoscopy using a CO2 laser or microdebrider every 3 months for the duration of the study, with intermediate procedures performed if necessary to maintain an airway. Five months after enrollment, patients were randomized to 1 of 2 treatment groups. One group received PDT at 6 months, and the second was treated by surgery for 12 additional months before PDT, with the delayed group serving as a control group in addition to the control period before PDT for each patient. A random numbers table was used to generate random assignments to treatment groups at Long Island Jewish Medical Center, and the randomizations were transmitted to the surgeon by the nurse clinician either personally or by telephone; the randomization ratio was 1:1. Patients and physicians were not masked to treatment group. All patients were followed up with scheduled endoscopies every 3 months for at least 12 months after PDT. A biopsy sample from clinically normal tissue was collected 9 to 12 months after PDT for analysis of HPV DNA persistence. Blood samples were collected at multiple times after PDT from a subset of patients treated at Long Island Jewish Medical Center to measure host immune response to HPV protein.

PARTICIPANTS

Patients older than 2 years with multiple papilloma recurrences requiring surgical removal 3 or more times per year or tracheobronchial involvement were eligible for enrollment. Patients were recruited from the practices of the investigators and by referral from other otolaryngologists between January 1, 1996, and December 31, 2002. Evaluations were performed before and after PDT at any of the participating sites, but each patient was followed at a single site. Data were analyzed at Long Island Jewish Medical Center and Montefiore Medical Center. All patients or guardians signed informed consent forms before enrollment. The study was approved by the institutional review board of the Institute for Medical Research and had Food and Drug Administration approval to use m-THPC (Foscan; Scotia Pharmaceuticals Ltd, Stirling, Scotland) as an investigational new drug.

INTERVENTION

At enrollment, patients underwent chest radiography, a complete blood cell count with a differential count, liver function tests, and urine analysis, followed by direct laryngoscopy with removal of all visible papillomas using a CO2 laser or microdebrider. Blood tests and urine analyses were repeated before the administration of m-THPC and 3 and 9 months after PDT. Six days before PDT, patients received 0.15 mg/kg of body weight of m-THPC intravenously as an outpatient. Just before PDT, blood samples were collected to determine plasma drug levels, as previously described elsewhere.16 Infusion of m-THPC and PDT were performed at Long Island Jewish Medical Center. At PDT, endoscopic laryngoscopy, and bronchoscopy if indicated, was performed using jet ventilation as previously described elsewhere.15 Activating light at 652 nm was delivered by a diode laser (Ophir Optronics, Inc, Wilmington, Mass) with a 400-μm-diameter quartz fiber with a 1.5- to 3.0-cm cylindrical diffuser tip. The light dose ranged from 80 to 100 J for adults and 60 to 80 J for children, depending on the concentration of drug in the plasma at the time of PDT. Total activation time varied from 200 to 330 seconds, with the patient apneic to reduce any movement of the centrally located fiber. The jet ventilation needle was withdrawn into the scope to avoid any shadow effect, which could decrease the effectiveness of the therapy.

MONITORING AND EVALUATION

At each endoscopy, before and after PDT, the extent of disease was scored and photodocumented on videotape by each treating physician as previously described elsewhere,14,15 assessing the number of disease sites, the surface area involved, and the extent of lumen obstruction. Rate of papilloma growth within the interval (severity score) was calculated as the total papilloma score divided by the number of days since the last surgical removal. For patients who required intermediate procedures between the scheduled endoscopies, scores for each subinterval were summed and then divided by the total number of days in the scheduled interval.

STATISTICAL ANALYSIS

An initial power analysis determined that for a 2-tailed test with a type 1 error of 0.05, 28 patients would be required in each group to demonstrate a 50% difference in the growth rate across time with 90% power. We could not recruit the desired number of patients, but the effect of PDT was greater than 50% (see the “Results” section), permitting determination of statistical significance. There were several reasons for the limited enrollment: the study design required that some patients wait 18 months after enrollment before receiving PDT, concerns about photosensitivity restricted enrollment during those months that would have resulted in PDT during the summer, and the absence of an immediate response caused many patients and physicians to conclude that the treatment was not effective.

Analysis was performed using a statistical software program (SAS version 8.2; SAS Institute Inc, Cary, NC). Hierarchical linear models, which do not generate means and standard deviations, were used to determine the significance of differences across time between the 2 treatment groups (early vs late PDT, considered to be the concurrent control during the first 9 months after randomization). The units of analyses were the participants’ “average scores per day” (referred to subsequently as “scores”) and the percentage change from randomization relative to the score obtained at the initial surgery. This model was optimal because it allowed for missing observations at various times. For a particular assessment date, time was computed as the number of days from the date of entry (first surgery) to that assessment date. Covariance structures for several models (random effects, compound symmetry, autoregressive, unstructured, and regression) were examined for data from the entire period, and the model that yielded the smallest magnitude of the Akaike Information Criterion was cited as the best model. Additional models were derived for selected periods (ie, for the first 9 months after the early group was treated with PDT, or longer) to best isolate periods in which differences between groups were significant. In addition, data from the time at which the individual received treatment through follow-up were pooled for all treated patients, with the assessment at which treatment was initiated considered the baseline among these treated patients. Hierarchical linear models were derived to determine the significance of trends over time. Analysis of response was performed according to the intention-to-treat principle. Treatment × time interactions for models comparing treatment effects and time for the pooled treated group were considered significant at P<.05. Associations between baseline characteristics and changes in scores and between groups were assessed using Spearman rank correlations, Wilcoxon rank sum and Kruskal-Wallis tests, and Fisher exact tests.

DNA ANALYSIS

DNA samples were extracted from biopsy samples and analyzed for latent HPV by polymerase chain reaction amplification, followed by Southern blotting for confirmation as previously described.2 Standard precautions to prevent polymerase chain reaction contamination were used. As a positive control, 25 fg of cloned HPV DNA was mixed with 50 ng of HPV-negative human tonsil DNA and amplified and analyzed at the same time as the biopsy DNA sample in each experiment. Amplification without the addition of tissue DNA served as a negative control for each assay. Clinically normal sites were biopsied using separate instruments that were not used on any active papillomas, and care was taken not to contaminate these specimens by contact with papilloma that might be present.

EVALUATION OF HOST IMMUNE RESPONSE

Expression of interferon γ (IFN-γ) and interleukin 10 (IL-10) messenger RNA cytokines by peripheral blood mononuclear cells was measured after exposure to HPV-11 E6 protein as described elsewhere.5 Briefly, peripheral blood mononuclear cells were incubated for 4 hours in recombinant E6 protein ranging from 50 to 0.2 ng/mL in 2-fold dilutions, and expression of IL-6 and IFN-γ messenger RNAs was determined. Cytokine-specific dose-response curves were generated for each patient’s peripheral blood mononuclear cells. The threshold of each dose-response curve was defined as the minimal concentration of viral protein required to increase the messenger RNA level greater than 2 SD above the mean, untreated baseline level. Thresholds were in the linear range for the detection of product.

RESULTS
PATIENTS

Twenty-three patients were initially enrolled in the study. Five patients withdrew after PDT when there was no immediate improvement and enrolled in other experimental treatments, and 1 relocated and was not followed up for the full 12 months. Fifteen patients received PDT followed by at least 1 year of scheduled evaluations. Two patients in the late PDT group withdrew after completion of the control period but before PDT, 1 owing to concerns about airway obstruction and 1 who had a spontaneous remission at the time of scheduled PDT. There were 12 patients in the early group and 5 in the late group available for analysis. Participant flow through the study is shown in Figure 1. Patient demographics and disease characteristics are given in Table 1. The ages of the patients at enrollment ranged from 4 to 60 years. At the time of PDT, there were 3 patients aged 4 to 9 years, 3 aged 10 to 20 years, 6 aged 21 to 40 years, and 5 aged 41 to 60 years. One adult had juvenile-onset disease, and the remaining had adult-onset disease. Of 5 patients with tracheal involvement, 1 underwent a tracheotomy before referral to Long Island Jewish Medical Center, and 1 had no laryngeal disease.

Table 2 gives the treatment variables for patients in the 2 groups (n = 3 for the late group because 2 patients were not treated). There was no significant difference in the light dose for the 2 groups. However, plasma levels of photosensitizer at time of PDT varied widely among patients (mean, 88 ng/mL; median, 91 ng/mL; range, 30-135 ng/mL [0.44 × 10−4M to 198.4 × 10−4M]), although all had received comparable doses based on body weight. This variation was consistent with an earlier preclinical study17 that showed marked variation in drug clearance between individual animals.

The most common adverse effect of PDT is skin photosensitivity, which is seen in all patients. Photosensitivity in the patients treated in this study required elimination of all sun and bright light exposure for 2 to 4 weeks. One patient disregarded instructions to avoid the sun and experienced erythema and swelling that lasted for several days. One patient, a young child with severe disease, experienced substantial swelling of the airway within a few hours of PDT that required intubation for several days to maintain an airway, prolonged hospitalization, and eventually a tracheotomy. Based on that event, the participating physicians recommended not performing PDT on the patient in the late group who had very extensive disease and a narrowed airway.

CLINICAL RESPONSE TO PDT

The primary goal of the study was to determine whether there is a reduction in severity of disease after PDT, as measured by the rate of papilloma regrowth. Figure 2 shows the median relative severity scores of laryngeal papillomas in the 2 groups of patients during the 18 months after enrollment, normalized to the severity score at study entry. There was increased variation for patients in the early treatment group 3 months after enrollment, reflecting increased severity in 2 patients and decreased severity in 1 patient. Most patients in both groups showed a modest relative decrease in disease severity during the 3- and 6-month pre-PDT evaluations, which continued at the 9-month evaluation in the control group. The decrease could reflect the effects of surgery at regular, relatively frequent intervals because other researchers19 have suggested that frequent removal of recurrent papillomas can modify the course of disease. Five patients had a worsening of disease severity after PDT that lasted for 3 to 5 months, whereas most patients had no change in disease severity during that period. In the worst case, 1 patient had a 7-fold increase in the rate of papilloma growth. However, there was a marked decrease in relative severity 6 to 9 months after treatment, with 5 (45%) of 11 patients in the early treatment group free of laryngeal disease. One of these was the patient with the worst exacerbation after PDT. Of patients who did not achieve remission by 15 months after PDT, 4 of 11 showed improvement of 40% to 50% compared with entry severity, and 2 showed no improvement (<25% change). The 12th patient in the early group had tracheal disease only and is not included in Figure 2. The remissions lasted for 3 to 5 years. Since then, 4 patients we have continued to follow have had small areas of recurrent papilloma that were easily treated using a CO2 laser (data not shown).

The first statistical analysis compared the early PDT–treated group with the concurrent control regarding follow-up points (before treatment for the late group) for laryngeal and tracheal scores. Percentage of change from baseline (randomization) was not performed because some scores were zero (undefined) at baseline. Instead, the score obtained at the initial assessment was used to derive the percentage of change. For analyses using data from all points, models for which treatment group and time were considered fixed effects and subject was considered random yielded lower Akaike Information Criterion values than other models for the same outcomes. Table 3 provides statistics for the analyses involving laryngeal and tracheal scores using 0, 3, and 6 months (randomization) and subsequent points until the late group was treated. The resulting Akaike Information Criterion values and corresponding P values for the analyses indicate that group × time interactions were statistically significant for laryngeal but not for tracheal models.

The significant interaction found for laryngeal scores likely indicates that there were differences between the groups during the times preceding randomization. There were too few degrees of freedom to analyze the difference between the groups regarding the times starting from the time of randomization. In addition, for tracheal scores, it seems that the 2 groups were significantly different throughout the assessment period (P = .01), indicating that randomization likely did not result in balanced groups. Regarding the analysis of differences in the percentage change scores (Table 3), differences between the early and late treatment groups seemed to increase later in the course of treatment. In contrast, median scores seemed to converge.

The final analyses were performed on the pooled treated cohorts (Table 3). There was a significant reduction from the initial evaluation in laryngeal score among those treated 6 months after the initial evaluation, with laryngeal values for the 12 months after PDT being significantly different from the 3 values preceding PDT (laryngeal Akaike Information Criterion percentage change, 1227.5; median scores, from 0.102 at entry to 0.04), and a significant reduction in disease (P = .007). For tracheal disease, the percentage change was not significant (P = .16), with median scores of 0.099 at entry and 0.111 at 12 months. The trend for change in disease severity before PDT for the delayed treatment (control) group was not significant (P = .44). We then asked whether response was associated with other variables, including plasma levels at the time of PDT. There was no association between demographic or treatment variables and response to PDT (Table 4).

EFFECTS ON PAPILLOMAVIRUS PERSISTENCE

We questioned whether the reduction in disease 1 year after PDT reflected a loss of latent HPV from the respiratory tissues in those patients. The prevalence of latent infection in the biopsy samples (n = 20) was 41%, comparable with our recent study2 of viral latency in patients treated with CO2 laser ablation, in which 44% were positive. This is a typical finding, suggesting that latent infection is “patchy” but widespread. The amount of HPV DNA in the biopsy samples varied but was generally in the range of 0.1 to 1.0 copy per cell compared with amplification of cloned HPV DNA. Remission was not due to elimination of latent HPV infection.

CHANGE IN HOST IMMUNE RESPONSE AFTER PDT

Patients with RRP do not mount an effective immune response to HPV proteins,4 with a correlation between the amount of HPV E6 protein required to induce response and disease severity.5 We asked whether PDT altered immune response to E6, and whether this could explain the pattern of delayed response. Figure 3 shows the concentration of E6 required to induce IL-10 and IFN-γ messenger RNA expression by peripheral blood mononuclear cells from 3 patients compared with disease severity at the time of each analysis. Interferon γ is important in the control of viral infections, whereas IL-10 is immunosuppressive. The amount of E6 required to induce IFN-γ and IL-10 expression by the 3 patients decreased when disease severity improved after PDT and increased when patients showed worsening of their disease. Two patients (Figure 3A and B) required comparable concentrations of E6 to induce IL-10 and IFN-γ, whereas the third patient (Figure 3C) required different amounts of E6 to induce the 2 cytokines. Increased amounts of E6 were required by this patient to induce IFN-γ when his severity score significantly worsened 3 months after PDT, and again 13 months after PDT, possibly predicting future worsening of disease. We did not assess the patient’s subsequent disease severity to determine whether this was true.

COMMENT

The concept of using a photosensitive dye activated by light to destroy tumor cells has a long history.20 We applied it to the treatment of benign papillomavirus-induced lesions, using hematoporphyrin derivative and dihematoporphyrin-ether photosensitizers in preclinical and clinical studies1215 and m-THPC in preclinical studies.1618 This article describes the effects of m-THPC PDT on RRP.

Several conclusions can be drawn from the study. First, most patients responded to treatment, but the response was delayed, with an initial transient increase in disease severity in many patients. The small sample size provided limited power for assessment of responses between the PDT arm and its concurrent control, and the effect observed in the pooled treated groups may have been due to natural reduction in severity of disease across time. However, we would not have expected the marked median improvement seen 12 months after treatment (Figure 2). Second, patients who were followed up after completing the study had small recurrences 3 to 5 years later, but the rate of recurrence was reduced compared with their original pattern. Third, clinical improvement did not reflect elimination of latent viral DNA, consistent with previous studies15 of dihematoporphyrin-ether PDT, explaining the recurrence of disease after several years of remission in this study. Instead, our results suggest that PDT altered the host immune response to viral proteins. This mechanism is consistent with findings from a previous study indicating that PDT induced cytotoxic T cells in mice with subcutaneous tumors21 and with the recent suggestion that the effects of PDT on the immune response to cancer are mediated by an in situ “vaccination” mediated by local release of tumor antigens by necrosis.22

In contrast to laser or mechanical surgical removal, PDT induces slow necrotic destruction of papilloma tissue. Thus, released HPV proteins would be more likely to interact with antigen-presenting cells, for example, Langerhans cells, which present the antigens to T cells in regional lymph nodes. A rapid increase in the amount of HPV proteins in the absence of concomitant maturation of presenting cells could cause a shift in HPV-specific immune responses from low HPV protein level T-cell ignorance/tolerance to high HPV protein level T-cell suppression/anergy,23 resulting in temporary worsening of disease. With time, in the context of more matured presenting cell function, immune response would increase and disease would improve. However, when remission was achieved it was not permanent, suggesting that PDT effects on the immune system are insufficient to maintain improved T-cell responses to HPV.

A previous study5 showed that patients with severe RRP express relatively more IL-10 than IFN-γ when challenged with E6 protein. Genetic polymorphisms associated with immune response genes are important in predicting disease severity and predisposition to RRP.24,25 Therefore, genetic factors are likely to be important in generating competent HPV-specific immunity, and they may play a major role in determining the long-term effects of PDT for RRP.

In conclusion, PDT with m-THPC showed significant efficacy in the treatment of RRP, probably reflecting improvement in the immune response by indirectly immunizing the patient to HPV proteins. However, the effects were not permanent, possibly owing to a relatively short-term immune improvement.

Back to top
Article Information

Correspondence: Mark J. Shikowitz, MD, Department of Otolaryngology and Communicative Disorders, Long Island Jewish Medical Center, 270-05 76th Ave, New Hyde Park, NY 11040 (mshikowi@lij.edu).

Submitted for Publication: September 2, 2004; accepted October 21, 2004.

Funding/Support: This study was supported by grant P50 DC00203 from the National Institute on Deafness and Other Communication Disorders, Bethesda, Md, and by a grant from the Irving and Helen Schneider Family Foundation, New York, NY.

References
1.
Steinberg  BMTopp  WSchneider  PSAbramson  AL Laryngeal papillomavirus infection during clinical remission. N Engl J Med 1983;3081261- 1264
PubMedArticle
2.
Abramson  ALNouri  MMullooly  VFisch  GSteinberg  BM Latent human papillomavirus infection is comparable in the larynx and trachea. J Med Virol 2004;72473- 477
PubMedArticle
3.
Broker  TRJin  GCroom-Rivers  A  et al.  Viral latency: the papillomavirus model. Dev Biol (Basel) 2001;106443- 451
PubMed
4.
Bonagura  VRHatam  LDeVoti  JZeng  FSteinberg  BM Recurrent respiratory papillomatosis: altered CD8(+) T-cell subsets and TH1/TH2 cytokine imbalance. Clin Immunol 1999;93302- 311
PubMedArticle
5.
DeVoti  JASteinberg  BMRosenthal  DW  et al.  Failure of gamma interferon but not interleukin-10 expression in response to human papillomavirus type 11 E6 protein in respiratory papillomatosis. Clin Diagn Lab Immunol 2004;11538- 547
PubMed
6.
Healy  GBGelber  RDTrowbridge  ALGrundfast  KMRuben  RJPrice  KN Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. N Engl J Med 1988;319401- 407
PubMedArticle
7.
Kashima  HLeventhal  BClark  K  et al.  Interferon α-Na in juvenile onset recurrent respiratory papillomatosis: results of a randomized study in twelve collaborative institutions. Laryngoscope 1988;98334- 340
PubMed
8.
Auborn  KJ Therapy for recurrent respiratory papillomatosis. Antivir Ther 2002;71- 9
PubMed
9.
Rosen  CABryson  PC Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results. J Voice 2004;18248- 253
PubMedArticle
10.
Pashley  NR Can mumps vaccine induce remission in recurrent respiratory papilloma? Arch Otolaryngol Head Neck Surg 2002;128783- 786
PubMedArticle
11.
Pransky  SMMagit  AEKearns  DBKang  DRDuncan  NO Intralesional cidofovir for recurrent respiratory papillomatosis in children. Arch Otolaryngol Head Neck Surg 1999;1251143- 1148
PubMedArticle
12.
Shikowitz  MJSteinberg  BMAbramson  AL Hematoporphyrin derivative therapy of papillomas: experimental study. Arch Otolaryngol Head Neck Surg 1986;11242- 46
PubMedArticle
13.
Abramson  ALShikowitz  MJMullooly  VMSteinberg  BMAmela  CARothstein  HR Clinical effects of photodynamic therapy on recurrent laryngeal papillomas. Arch Otolaryngol Head Neck Surg 1992;11825- 29
PubMedArticle
14.
Abramson  ALShikowitz  MJMullooly  VMSteinberg  BMHyman  RB Variable light dose effect on photodynamic therapy of laryngeal papillomas. Arch Otolaryngol Head Neck Surg 1994;120852- 855
PubMedArticle
15.
Shikowitz  MJAbramson  ALFreeman  K  et al.  Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results. Laryngoscope 1998;108962- 967
PubMedArticle
16.
Ronn  AMNouri  MLofgren  LA  et al.  Human tissue levels and plasma pharmacokinetics of temoporfin (Foscan, mTHPC). Lasers Med Sci 1996;11267- 272Article
17.
Ronn  AMBatti  JLee  CJ  et al.  Comparative biodistribution of meta-tetra(hydroxyphenyl) chlorin in multiple species: clinical implications for photodynamic therapy. Lasers Surg Med 1997;20437- 442
PubMedArticle
18.
Lofgren  LARonn  AMAbramson  AL  et al.  Photodynamic therapy using m-tetra (hydroxyphenyl) chlorin: an animal model. Arch Otolaryngol Head Neck Surg 1994;1201355- 1362
PubMedArticle
19.
Dedo  HHYu  KC CO2 laser treatment in 244 patients with respiratory papillomas. Laryngoscope 2001;1111639- 1644
PubMedArticle
20.
Dougherty  TJGomer  CJHenderson  BW  et al.  Photodynamic therapy. J Natl Cancer Inst 1998;90889- 905
PubMedArticle
21.
Korbelik  MDougherty  GJ Photodynamic therapy–mediated immune response against subcutaneous mouse tumors. Cancer Res 1999;591941- 1946
PubMed
22.
van Duijnhoven  FHAalbers  RIRovers  JPTerpstra  OTKuppen  PJ The immunological consequences of photodynamic treatment of cancer, a literature review. Immunobiology 2003;207105- 113
PubMedArticle
23.
Ohashi  PSDeFranco  AL Making and breaking tolerance. Curr Opin Immunol 2002;14744- 759
PubMedArticle
24.
Bonagura  VRVambutas  ADeVoti  JA  et al.  HLA alleles, IFN-γ responses to HPV-11 E6, and disease severity in patients with recurrent respiratory papillomatosis. Hum Immunol 2004;65773- 782
PubMedArticle
25.
Vambutas  ABonagura  VRReed  EF  et al.  Polymorphism of transporter associated with antigen presentation 1 as a potential determinant for severity of disease in recurrent respiratory papillomatosis caused by human papillomavirus types 6 and 11. J Infect Dis 2004;189871- 879
PubMedArticle
×